Clinical trials · Pennsylvania
ER Positive Breast Cancer clinical trials in Pennsylvania
We’re tracking 41 recruiting er positive breast cancer studies with a site in Pennsylvania — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT05919108RecruitingPhase 2
Neratinib before surgery for HER2-mutated invasive lobular breast cancer
This Phase 2 trial tests neratinib given before surgery to treat stage I–III invasive lobular breast cancer that has a specific HER2 mutation and is hormone-receptor positive. It may help shrink the tumor and improve control of cancer before and after surgery.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05952557RecruitingPhase 3
Camizestrant after surgery for hormone-sensitive early breast cancer
This trial studies whether adding camizestrant (a hormone-blocking medicine) after breast cancer surgery can lower the chance the cancer returns in ER+/HER2− early breast cancer. It is designed for people who have had definitive local treatment and are being considered for additional “prevention” hormone therapy.
Gettysburg, PennsylvaniaAges 18–130 - NCT06016738RecruitingPhase 3
Palazestrant vs standard therapy for advanced breast cancer
This trial compares a new oral drug, palazestrant (OP-1250), to standard hormone therapies for people with ER+/HER2- advanced breast cancer that has worsened after prior hormone therapy. It tests whether palazestrant can better control the cancer.
Sayre, PennsylvaniaAges 18 years+ - NCT06492616RecruitingPhase 3
Elacestrant vs standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy pill (elacestrant) against standard hormone therapy for people with a common type of early breast cancer (ER+, HER2-) that has a higher chance of returning. You may qualify if you've already been on hormone therapy for 2 to 5 years and want to see if a different pill works better.
Allen, PennsylvaniaAges 18 years+ - NCT06966453RecruitingPhase 1/Phase 2
Study of disitamab vedotin for HER2-positive advanced breast cancer
This study tests a new drug called disitamab vedotin for people with advanced breast cancer that has a certain amount of HER2 protein. Depending on your HER2 and hormone receptor status, you may be eligible for one of three groups, each with different prior treatment requirements.
Doylestown, PennsylvaniaAges 18 years+ - NCT07214532Recruiting
Guiding CDK4/6 inhibitor use by a blood test in breast cancer
This trial is for women and men with early-stage, hormone-positive, HER2-negative breast cancer. It uses a blood test (Signatera) to detect tiny amounts of cancer DNA and only starts a CDK4/6 inhibitor (ribociclib or abemaciclib) if the test shows cancer DNA is present.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07262138Recruiting
Active monitoring for older women with early breast cancer
This trial studies whether active monitoring (watchful waiting) can be a safe option instead of immediate surgery or other treatments for women 70 and older who have a small, slow-growing type of breast cancer. If you join, you will not have surgery or other treatments right away, but your cancer will be closely watched.
Pittsburgh, PennsylvaniaAges 70 years+ - NCT01042379RecruitingPhase 2
Adaptive drug trial for newly diagnosed breast cancer
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Pittsburgh, PennsylvaniaAges 18 years+ - NCT02732171Recruiting
Blood and bone marrow tests to track breast cancer return
This trial checks whether specific “surveillance” markers (measured from blood and bone marrow) can help predict if breast cancer comes back after standard treatments. It may help doctors monitor you more accurately and earlier if recurrence risk is high.
Philadelphia, PennsylvaniaAges 18 years+ - NCT02945579Recruiting
Testing skipping breast surgery or radiation for top responders
This trial studies whether some people with early-stage breast cancer who respond extremely well to hormone/chemo/targeted treatment can safely skip breast surgery and/or radiation. It aims to reduce side effects without increasing cancer risk in carefully selected patients.
Pittsburgh, PennsylvaniaAges 30 years+ - NCT07310420RecruitingPhase 1
Zoladex injection for ovarian suppression in advanced breast cancer
This trial tests a single injection of Zoladex (goserelin) to see how well it suppresses ovarian function in premenopausal women with HR+, HER2- advanced breast cancer. It may be an option if you are still having periods and your cancer has spread or cannot be removed by surgery.
Bethlehem, PennsylvaniaAges 18–55 - NCT04852887RecruitingPhase 3
Testing shorter breast radiation after low-risk hormone breast cancer
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Chambersburg, PennsylvaniaAges 50–70 - NCT06923527RecruitingPhase 2
Testing ctDNA to start elacestrant in early breast cancer
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07174336RecruitingPhase 3
Testing Tersolisib with other treatments for advanced breast cancer
This trial tests a new study drug called Tersolisib combined with other anti-cancer treatments for people with advanced breast cancer that has a specific gene change (PIK3CA). The goal is to see if the combination can help shrink or slow the cancer.
Bethlehem, PennsylvaniaAges 18 years+ - NCT07332975Recruiting
Blood test for tumor DNA in early triple-negative breast cancer
This study is for people with early-stage triple-negative breast cancer (TNBC) that has not been treated yet. Researchers want to see if tracking tumor DNA in your blood can help guide treatment decisions. You would receive standard chemotherapy and surgery, plus give blood samples.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
Broomall, PennsylvaniaAges 18 years+ - NCT07114601RecruitingPhase 1
Study of LY4257496 for people with GRPR-positive solid tumors
This trial tests a new drug, LY4257496, in people with certain types of cancer that have a protein called GRPR on their cells. The study aims to see if the drug can help shrink tumors or slow the cancer's growth.
Pittsburgh, PennsylvaniaAges 18 years+
ER Positive Breast Cancer trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting er positive breast cancer studies listed above.
- University of Pennsylvania · 4 studies
- University of Pittsburgh Medical Center · 4 studies
- St. Luke's University Health Network · 3 studies
- Allegheny General Hospital · 2 studies
- Alliance Cancer Specialists · 2 studies
- Asplundh Cancer Pavilion · 2 studies
- Cancer Care Associates of York · 2 studies
- Crozer-Keystone Regional Cancer Center at Broomall · 2 studies
What taking part in a er positive breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
ER Positive Breast Cancer trials in other states
Common questions
- Are there er positive breast cancer clinical trials in Pennsylvania?
- Yes. We're currently tracking 41 recruiting er positive breast cancer studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a er positive breast cancer study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a er positive breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New er positive breast cancer studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.